Incidence and Survival Among Young Women With Stage I–III Breast Cancer: SEER 2000–2015

Abstract

Background Although recent findings suggest that de novo stage IV breast cancer is increasing in premenopausal women in the United States, contemporary incidence and survival data are lacking for stage I–III cancer. Methods Women aged 20–29 (n = 3826), 30–39 (n = 34 585), and 40–49 (n = 126 552) years who were diagnosed with stage I–III breast cancer from 2000 to 2015 were identified from the Surveillance, Epidemiology, and End Results 18 registries database. Age-adjusted, average annual percentage changes in incidence and 5- and 10-year Kaplan-Meier survival curves were estimated by race and ethnicity, stage, and hormone receptor (HR) status and grade (low to well and moderately differentiated; high to poorly and undifferentiated) for each age decade. Results The average annual percentage change in incidence was positive for each age decade and was highest among women aged 20–29 years. Increased incidence was driven largely by HR+ cancer, particularly HR+ low-grade cancer in women aged 20–29 and 40–49 years. By 2015, incidence of HR+ low- and high-grade cancer each independently exceeded incidence of HR− cancer in each age decade. Survival for HR+ low- and high-grade cancer decreased with decreasing age; survival for HR− cancer was similar across age decades. Among all women aged 20–29 years, 10-year survival for HR+ high-grade cancer was lower than that for HR+ low-grade or HR− cancer. Among women aged 20–29 years with stage I cancer, 10-year survival was lowest for HR+ high-grade cancer. Conclusions HR+ breast cancer is increasing in incidence among premenopausal women, and HR+ high-grade cancer was associated with reduced survival among women aged 20–29 years. Our findings can help guide further evaluation of preventive, diagnostic, and therapeutic strategies for breast cancer among premenopausal women.

Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016

“…Missing data on molecular subtype were more common in Hispanic women overall and women aged 70 to 84 years in each race/ethnic group (eTable in the Supplement ). 5 …”

“…Population-based studies suggest a mostly stable trend in overall breast cancer incidence rates, 1 , 2 although there are documented differences in trends by age at diagnosis and racial/ethnic groups. 1 , 3 , 4 , 5 Moreover, studies have reported racial/ethnic differences in the incidence rates of breast cancer subtypes, defined according to hormone receptor status or ERBB2 (formerly HER2) receptor status, but these studies have mostly considered few broad molecular subtype, race/ethnicity, or age categories. 6 , 7 , 8 A 2019 report 2 of temporal changes in breast cancer incidence rates from 2004 through 2016, which used only breast cancer subtypes by hormone receptor status, found that incidence rates increased for hormone receptor–positive breast cancers (corresponding to both luminal A and B molecular breast cancer subtypes) for all races/ethnicities, although rates began to stabilized after 2011 for non-Hispanic Black and American Indian and Alaska Native women.…”

Pyrotinib sensitizes 5‑fluorouracil‑resistant HER2-positive breast cancer cells to 5‑fluorouracil

“…Breast cancer is the common female tumor [1] and sensitive to chemotherapeutic agent. Among the agents, 5-FU was widely used for the treatment of breast cancer.…”

A Comparative Analysis of Data Mining Techniques on Breast Cancer Diagnosis Data using WEKA Toolbox

“…The rapid spread of breast cancer and the inability to accurately diagnose and recognize its presence represents a challenge for researchers and developers in biomedical engineering [2]. This challenge leads to deploying new data mining techniques.…”